MedPath

HOKKAIDO GASTROINTESTINAL CANCER STUDY GROUP

🇯🇵Japan
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

18

Active:0
Completed:9

Trial Phases

4 Phases

Phase 1:7
Phase 2:3
Phase 3:2
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials

Phase 1
7 (38.9%)
Not Applicable
6 (33.3%)
Phase 2
3 (16.7%)
Phase 3
2 (11.1%)

IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer

Phase 3
Suspended
Conditions
Metastatic Colorectal Cancer
Interventions
Drug: L-Plat
Drug: Campto, Topotesin
First Posted Date
2006-04-21
Last Posted Date
2007-11-01
Lead Sponsor
Hokkaido Gastrointestinal Cancer Study Group
Target Recruit Count
200
Registration Number
NCT00316745
Locations
🇯🇵

Hokkaido University Hospital (Hokkaido University Graduate School of Medicine / School of Medicine), Sapporo, Hokkaido, Japan

Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer

Phase 2
Suspended
Conditions
Gastric Cancer
First Posted Date
2005-09-21
Last Posted Date
2006-02-02
Lead Sponsor
Hokkaido Gastrointestinal Cancer Study Group
Target Recruit Count
40
Registration Number
NCT00209664
Locations
🇯🇵

Hokkaido University Hospital, Sapporo, Hokkaido, Japan

Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer

Phase 2
Conditions
Colorectal Cancer
Interventions
Drug: Campto, Topotesin
First Posted Date
2005-09-21
Last Posted Date
2007-11-01
Lead Sponsor
Hokkaido Gastrointestinal Cancer Study Group
Target Recruit Count
40
Registration Number
NCT00209651
Locations
🇯🇵

Hokkaido University Hospital, Sapporo, Hokkaido, Japan

Phase I/II Study of Oral S-1 Plus Docetaxel in Elderly Patients With Advanced Gastric Cancer.

Phase 1
Suspended
Conditions
Gastric Cancer
Interventions
First Posted Date
2005-09-21
Last Posted Date
2010-05-26
Lead Sponsor
Hokkaido Gastrointestinal Cancer Study Group
Target Recruit Count
50
Registration Number
NCT00209729
Locations
🇯🇵

Hokkaido University Hospital (Hokkaido University Graduate School of Medicine), Sapporo, Hokkaido, Japan

Phase I/II Study of Taxotere,CDDP and 5-FU(TPF) in Pre-treated Pts With Metastatic Esophageal Cancer.

Phase 1
Completed
Conditions
Esophageal Cancer
Interventions
First Posted Date
2005-09-21
Last Posted Date
2010-05-26
Lead Sponsor
Hokkaido Gastrointestinal Cancer Study Group
Target Recruit Count
30
Registration Number
NCT00209716
Locations
🇯🇵

・ Hokkaido University Hospital (Hokkaido University Graduate School of Medicine), Sapporo, Hokkaido, Japan

  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.